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Purpose: Tibial osteotomy is a treatment for younger and/or
physically active patients suffering from uni-compartmental knee
osteoarthritis. The treatment intends to delay the disease pro-
gression and to stop the pain by realigning the tibia.
The aim of this study is to analyse cartilage changes in the knee
joint after High Tibial Osteotomy (HTO).
Methods: Consecutive subjects with osteoarthritis (OA) of the
knee who were placed on a waiting list for HTO surgery were
invited to take part in the MRI outcome study. Subjects were
examined before the surgery and during their first follow-up visit
(7±1 months). Further follow-up is planned for 12 and 24 months.
Primary outcome was tibiofemoral cartilage morphology mea-
sured by means of a 3 Tesla MRI scanner (Magnetom Trio,
Siemens AG, Erlangen, Germany). A previously validated fat-
suppressed gradient echo sequence with an in plane resolution
of 0.312x0.312mm and a slice thickness of 1.5 mm (repetition
time 31ms, echo time 10 ms, flip angle 20) was used. The sagittal
MRI’s were segmented by one blinded assessor using Chondro-
metrics software (Ainring, Germany). Three-dimensional mor-
phology of the tibial and femoral cartilage (mean and maximum
thickness, volume, and denuded surface area) was calculated.
The static alignment of the knee was determined from standing
full limb radiographs. The mechanical axis represents the angle
formed between an axis from the center of the femoral head to
the centre of the knee and an axis from the centre of the knee
to the centre of the ankle. The Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) was used to assess
the effect of the treatment on the symptoms of OA.
A Wilcoxon Paired-Samples Test was used to assess statistical
significance of the differences between baseline and follow up
measurement in the patients. A significance level of 0.05 was
chosen unless otherwise indicated.
Results: A total of 12 subjects were included in the study. Three
female and 8 males with a mean (SD) age of 52 (4.5) years and a
Body Mass Index of 30 (4.4) kg/m2 were measured at baseline.
Baseline WOMAC score was 71.3 (17.1). Eight subjects had
their first follow-up MRI. One subject was lost for follow-up and 3
subjects haven’t reached their first follow-up appointment. Due to
imaging artefact the MRI of one subject couldn’t be segmented.
None of the morphological parameters showed a significant
change in any of the joint compartments (Table 1). We observed
a decrease in the medial cartilage volume (medial tibia and
P367 – Table 1. Pre- and Post-injection pain in Painful TKAs after IA-BoNT/A
Patient Daytime Pain on (0-10) NRS Nighttime Pain on (0-10) NRS Onset of Pain Relief
Pre-injection Post-injection % Improvement Pre-injection Post-injection % Improvement
Pt. 1: 73 M-R*‡ 5 3.5 30% 5 1 80% 7 days
Pt. 1: 73 M-L 6 3.5 42% 10 1 90% 7 days
Pt. 2: 56 F-R 5 2 60% 5 2 60% 7 days
Pt. 3: 81 M-R‡ 8 7.5 6% 2.5 2 20% No relief
Pt. 4: 65 M-R 7.5 3 60% 3 2 33% 11 days
Pt. 5: 56 M-L 7 1 86% 0 0 N/A 6 days
*Patient 1 had bilateral knee injection; ‡Patients who received the second injection; M, male; F, female; R, right; L, left; NRS, Numeric rating scale.
Table 1. Knee Cartilage Mean Thickness at Baseline and 6 Month Post HTO
Compartment Cartilage Thickness (mm)
Baseline Follow-up
Medial Tibia 1.58 ± 0.20 1.47 ± 0.21
Medial Femur 1.67 ± 0.41 1.61 ± 0.46
Lateral Tibia 2.34 ± 0.28 2.26 ± 0.16
Lateral Femur 2.32 ± 0.51 2.29 ± 0.43
femur) in six out of the seven patients. Symptoms were however
significantly improved 7 months after surgery (p<0.05).
Conclusions: We could not detect any regeneration of articular
cartilage within 7 months post surgery. To the contrary a trend to
a decrease in cartilage thickness could be detected in some joint
surfaces. The cause of this is not immediately apparent. It may
be explained in part by early post surgical immobilisation and
changes in weight bearing. Longer followup and a larger study
group are planned and may help clarify these early findings.
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Purpose: The painful TKA without clear etiology can be a difficult
management problem. We report data on off-label use of IA-
BoNT/A for refractory painful TKAs.
Methods: A case-series of five patients with six refractory painful
TKAs with pain >12-months received 100-units of IA-BoNT/A in
the painful joint followed by a re-injection of 200-units 8-12 weeks
later, if there was no relief with the initial injection. All conser-
vative therapeutic options including oral analgesics and anti-
inflammatory medications had been exhausted in these patients.
Infection, prosthetic loosening, and other surgically correctable
causes of pain were ruled out. Data were collected prospectively
under the purview of a Quality Assurance/Quality Improvement
initiative.
Pre- and post-injection data were collected prospectively: pain
severity on a 0-10 numeric rating scale (NRS), onset and dura-
tion of pain relief, patients’ global assessment of change (very
much improved, much improved, minimally improved, no change,
minimally worse, much worse, very much worse) and adverse
effects. Pain severity reduction of ≥ 30% (or 2-points on 0-10
scale) and ≥ 50% have been adjudicated as clinically meaningful
in patients in meta-analysis of pain trials (correlating with "much
improved" and "very much improved" categories respectively).
Results: Five patients had six painful TKAs injected (bilateral
TKA in one patient). Five of the six injected TKAs (80%) had
pain relief (Table 1). 5/6 painful TKAs had clinically significant
relief in Daytime pain (≥30% reduction) and 3/6 TKAs had ex-
cellent pain relief (≥50% reduction). Night time pain reduction
was significant in 4/5 and excelent in 3/5 TKAs (pain level was
0 in one patient at baseline). 5/6 painful TKAs had "much im-
provement" on patient global assessment. Pain relief started
6-11 days after the injection and lasted from 3 to 26 weeks
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(maximum duration pending complete follow-up). Two patients
received the 200 units IA BoNT/A injection 8-12 weeks after the
first injection (including the only non-responder).
No increase in joint inflammation, periarticular muscle weakness,
fever or fatigue, or other complications were noted.
Conclusions: I/A BoNT/A significantly decreased refractory
prosthetic joint pain and appeared to be safe. A prospective
randomized trial is underway to confirm these findings.
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Purpose: There is no consensus regarding the optimal strategy
to minimise patients exposure to allogenic blood transfusion. The
majority of current literature suggests tranexamic acid reduces
blood loss following hip and knee arthroplasty.
The aim of this study is to determine whether these findings
are reproducible despite variations in surgical practice, whether
tranexamic acid has any effect on the length of inpatient stay
and whether there are any unwanted complications secondary
to administration.
Methods: Retrospective analysis of case notes.
Included all patients undergoing primary THR and TKR between
Jan 2005 to Dec 2005 under care of the senior author.
74 patients in total.
Aetiology was osteoarthritis in all cases.
Exclusions: Missing case notes 11, no documentation of blood
loss in drain 10
52 patients included in study
26 underwent primary TKR (13 had 1g i.v tranexamic acid
at induction and before release of tourniquet after cementing
prosthesis)
26 underwent primary THR (13 had 1g i.v tranexamic acid at
induction)
39 operated by senior surgeon
13 operated by trainees with senior author supervising
Blood loss in drain, pre and post op Hb, length of inpatient stay
and post operative complications were recorded in all cases.
Differences between the control group and those receiving
tranexamic acid were analysed using a Students T-test, with
p<0.05 taken as statistically significant.
Results: THR (comparing difference between tranexamic acid
group and control).
Mean drop in Hb was less in the tranexamic acid group p=0.019
Mean blood loss in drain was less in the tranexamic acid group
p=0.00039
Mean length of inpatient stay was less in the tranexamic acid
group p=0.012
Number of patients needing transfusion =4 in control group
compared to 0 in the tranexamic acid group
No of post operative P.E = 1 in tranexamic acid group compared
to 0 in the control group TKR (comparing difference between
tranexamic acid group and control).
Mean drop in Hb was less in the tranexamic acid group p=0.299
Mean blood loss in drain was less in the tranexamic acid group
p=0.00039
Mean length of inpatient stay was less in the tranexamic acid
group p=0.0124
No of patients needing transfusion =3 in control group compared
to 1 in the tranexamic acid group
Number of post operative P.E =2 in tranexamic acid group com-
pared to 0 in the control group
Conclusions: This study adds to the body of evidence which
supports the use of tranexamic acid in elective primary hip and
knee arthroplasty.
Statistically significant decreased blood loss in the drain when
administering tranexamic acid during THR and TKR
Statistically significant reduction in the Hb drop post operatively
when administering tranexamic acid during THR.
Clinically significant reduction in inpatient stay in those patients
who received tranexamic acid.
Results achieved despite variations in methodology to previous
studies and variation in surgical technique to previous studies.
Weaknesses of study is selection bias and limited sample size.
More research is required to determine optimum dose and timing
of administration.
The routine use of this antifibrinolytic should be considered for
patients undergoing elective primary THR and TKR.
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ABRASION ARTHROPLASTY WITH OSTEOTOMY FOR
MEDIAL COMPARTMENT OSTEOARTHRITIS OF THE
KNEE - A VIABLE ALTERNATIVE TO
UNICOMPARTMENTAL OR TOTAL KNEE JOINT
REPLACEMENT
J. Toft, A. Vilas-Boas
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Purpose: The objective of this study is to demonstrate that
for medial compartment knee arthritis abrasion arthroplasty and
osteotomy can be a viable alternative to replacement surgery.
Methods: Between 1989 and 2002, 486 medial compartment
abrasion arthroplasties with valgus osteotomy were performed.
The Oxford Knee Questionnaire was sent to 470 patients, of
which 296 were correctly answered. All patients had grade III/IV
(Outerbridge) cartilage lesions.34 patients were bilateral. The
minimum follow-up was 12 months, and the maximum was 14,
4 years, which means an average of 2, 99 years. The abrasion
arthroplasty was performed with an abrader, combined with mi-
cro picks. The osteotomy was a closing-wedge osteotomy, with
proximal fibular lysis and internal fixation. All patients followed a
12-week non-weightbearing protocol.
Results: The mean knee score for patients treated by abrasion
arthroplasty and osteotomy was 38, 10 ± 8, 04. Of the 296
patients,133 (44.93%) had one or more surgeries before the
